Your cells build nucleotides, the molecular units that make up DNA and RNA, through two fundamentally different strategies. The de novo pathway assembles them from scratch using small, simple molecules like amino acids, carbon dioxide, and sugar-phosphate precursors. The salvage pathway recycles bases and nucleosides that come from the normal breakdown of old DNA and RNA, or from the diet. Both routes run simultaneously in most tissues, though their relative contributions shift depending on whether a cell is actively dividing, sitting quietly, or fighting off an infection. Understanding how these pathways work, and what goes wrong when they fail, turns out to matter for everything from gout to cancer treatment to the design of antiparasitic drugs.
Building Purines From Scratch
Purines (adenine and guanine) are the larger of the two nucleotide families. Cells construct the purine ring one atom at a time, directly on a sugar-phosphate backbone. The starting material is a molecule called PRPP (phosphoribosylpyrophosphate), and through ten sequential enzymatic steps the cell arrives at inosine monophosphate, or IMP, which serves as the common precursor for both adenine and guanine nucleotides.1PubMed. Disorders of purine biosynthesis metabolism IMP then branches: one path converts it to AMP (the adenine nucleotide), and the other converts it to GMP (the guanine nucleotide). The atoms that get added along the way come from glycine, glutamine, aspartate, carbon dioxide, and derivatives of the vitamin folate. Each atom in the finished purine ring has a traceable origin in one of these donors.
What makes the purine assembly line particularly interesting is how compact the cellular machinery is. In humans, several of the ten steps are performed by multifunctional enzymes, proteins that catalyze two or three different reactions each.1PubMed. Disorders of purine biosynthesis metabolism This consolidation keeps the process efficient and allows the cell to channel intermediates from one reaction directly to the next without losing them to the surrounding fluid. Recent work has shown that these enzymes can even cluster together physically into temporary complexes called purinosomes, which assemble when the cell needs purines and disassemble when it doesn’t.
Building Pyrimidines From Scratch
Pyrimidines (cytosine, uracil, and thymine) are the smaller nucleotide family, and their construction follows a different logic. Instead of building the ring on a sugar-phosphate scaffold, cells first assemble the pyrimidine ring as a free molecule and then attach it to the sugar-phosphate afterward. The first three steps of this process, which are also the rate-limiting bottleneck, are handled by a single large multifunctional protein called CAD.2PubMed Central. Pyrimidine Biosynthetic Enzyme CAD: Its Function, Regulation, and Diagnostic Potential CAD funnels the starting ingredients, glutamine, bicarbonate, ATP, and aspartate, through its three active sites in succession, producing a ring intermediate called dihydroorotate. Subsequent enzymes finish the ring and attach it to a ribose-phosphate to yield UMP, the base pyrimidine nucleotide from which CTP (the cytosine nucleotide) is then made.
This “ring first, sugar second” order is the opposite of purines, and it has practical consequences. Because early pyrimidine intermediates are small, water-soluble molecules floating free in the cell, they can diffuse away or be diverted. CAD’s multifunctional design helps prevent that leakage by keeping intermediates close to the next active site.
How Cells Keep the Two Pathways in Check
Overproducing nucleotides wastes energy, while underproducing them stalls DNA replication. Cells solve this with feedback loops that sense end-product levels and dial production up or down accordingly.
For purines, the key control point is the very first committed enzyme in the pathway. This enzyme is an allosteric tetramer, meaning its activity changes shape and speed when specific molecules bind to it at regulatory sites. AMP, one of the finished purine nucleotides, acts as a feedback inhibitor: when AMP levels rise, it binds to both the active site and a separate regulatory site on the enzyme, shutting production down.3PubMed. Structure of the allosteric regulatory enzyme of purine biosynthesis GMP exerts a similar braking effect through its own binding site. The result is that a cell with plenty of purines automatically throttles back de novo synthesis.
For pyrimidines, feedback control centers on CAD. UTP, the uridine nucleotide that is one of the pathway’s end products, inhibits CAD by reducing the enzyme’s ability to grab onto magnesium ions and ATP, which it needs to function. Conversely, PRPP activates CAD by boosting that same magnesium affinity, essentially telling the enzyme “raw materials are abundant, keep going.”4PubMed. Regulation of the mammalian carbamoyl-phosphate synthetase II by effectors and phosphorylation Phosphorylation of CAD by growth-signaling kinases adds another layer: when the cell receives signals to grow and divide, phosphorylation pushes CAD away from its inhibited state, ramping up pyrimidine output to prepare for DNA replication.4PubMed. Regulation of the mammalian carbamoyl-phosphate synthetase II by effectors and phosphorylation
The Salvage Pathway and Why Recycling Matters
Building nucleotides from scratch is energetically expensive. Purine de novo synthesis alone consumes multiple ATP molecules per nucleotide produced. So cells run a parallel recycling program: the salvage pathway captures free bases and nucleosides released by normal DNA and RNA turnover, snaps them back onto a sugar-phosphate, and returns them to the nucleotide pool. This is faster and cheaper than building from scratch.
For purines, the most important salvage enzyme is HPRT (hypoxanthine-guanine phosphoribosyltransferase), which reattaches hypoxanthine and guanine to PRPP to regenerate IMP and GMP. A second enzyme, APRT, does the same for adenine. The traditional view held that quiescent, non-dividing cells rely almost exclusively on salvage while rapidly dividing cells lean more heavily on de novo synthesis. Recent quantitative work in live animals has complicated that picture. Tumors, which are the quintessential dividing tissue, turn out to depend on salvage to a much greater degree than expected, with circulating adenine and inosine serving as the most effective blood-borne purine precursors for both normal tissues and tumors.5PubMed Central. De novo and salvage purine synthesis pathways across tissues and tumors Hypoxanthine, long thought to be a major salvage substrate, is actually broken down quickly in living organisms and is poorly recycled, a finding that overturns decades of textbook assumptions.5PubMed Central. De novo and salvage purine synthesis pathways across tissues and tumors
Pyrimidine salvage is built around a different set of enzymes. Uridine kinase phosphorylates free uridine to regenerate UMP, and from there the cell can make CTP as well. A competing enzyme, uridine phosphorylase, breaks uridine down instead. The balance between these two enzymes determines whether a given uridine molecule gets recycled or degraded.6PubMed. Key role of uridine kinase and uridine phosphorylase in the homeostatic regulation of purine and pyrimidine salvage in brain Uridine-cytidine kinases also phosphorylate cytidine directly to CMP, adding another entry point into the salvage network.7PubMed Central. Characterization of uridine-cytidine kinase like-1 nucleoside kinase activity and its role in tumor growth
From RNA Building Blocks to DNA Building Blocks
Both de novo and salvage pathways initially produce ribonucleotides, the form used in RNA. To make DNA, cells need deoxyribonucleotides, which lack one oxygen atom on the sugar. A single enzyme, ribonucleotide reductase (RNR), performs this conversion for all four bases, stripping the 2′-hydroxyl group from each ribonucleotide diphosphate to generate the corresponding deoxyribonucleotide.8PubMed. Regulation of mammalian ribonucleotide reduction and dNTP pools after DNA damage and in resting cells
RNR is one of the most tightly regulated enzymes in the cell. It uses allosteric control to sense the relative levels of all four deoxyribonucleotide triphosphates and adjust which one it produces, ensuring that DNA synthesis gets a balanced supply.9PubMed Central. Structures of eukaryotic ribonucleotide reductase I provide insights into dNTP regulation An imbalanced pool, too much of one deoxyribonucleotide relative to the others, causes the DNA copying machinery to make errors. This is why RNR sits at a critical junction: it is the gatekeeper between nucleotide metabolism and genome integrity.
One DNA base, thymine, requires an additional dedicated step. Thymidylate synthase converts dUMP (deoxyuridine monophosphate) to dTMP (deoxythymidine monophosphate) by transferring a one-carbon unit from a folate cofactor. This reaction regenerates dihydrofolate, which must be reduced back to tetrahydrofolate by dihydrofolate reductase (DHFR) before it can participate again. The tight coupling of thymidylate synthesis to the folate cycle is the reason folate deficiency impairs cell division and why drugs that block DHFR (like methotrexate) are effective against rapidly dividing cells. A parallel version of this pathway also operates inside mitochondria, where a distinct set of enzymes, including a mitochondrial thymidylate synthase and a mitochondrial DHFR, produces dTMP for mitochondrial DNA maintenance.10PubMed Central. Identification of a de novo thymidylate biosynthesis pathway in mammalian mitochondria
Mitochondria Have Their Own Nucleotide Needs
Mitochondria maintain their own small circular genome, which requires a constant supply of deoxyribonucleotides for replication and repair, even in cells that have stopped dividing. Because de novo nucleotide synthesis enzymes are located in the cytoplasm, mitochondria depend heavily on salvage enzymes and nucleotide transporters to maintain their internal pools.11PubMed. Depletion of the other genome-mitochondrial DNA depletion syndromes in humans Mitochondria contain dedicated deoxyribonucleoside kinases that phosphorylate imported nucleosides into the triphosphate forms needed for DNA synthesis.
When these mitochondrial salvage enzymes are defective, the mitochondrial genome suffers. Mutations in genes encoding mitochondrial deoxyribonucleoside kinases, thymidine phosphorylase, or the adenine nucleotide translocator can all lead to mitochondrial DNA depletion syndromes, a family of severe diseases characterized by a loss of mitochondrial DNA copies and progressive organ failure.12PubMed Central. A review comparing deoxyribonucleoside triphosphate (dNTP) concentrations in the mitochondrial and cytoplasmic compartments of normal and transformed cells Tissues with high energy demands, like muscle and brain, are typically the first affected. The fact that mitochondrial nucleotide balance is maintained by salvage rather than de novo synthesis makes these organelles uniquely vulnerable to salvage pathway defects.
When Salvage Fails: Lesch-Nyhan Syndrome and Gout
The most dramatic illustration of what happens when purine salvage breaks down is Lesch-Nyhan syndrome. This rare inherited condition results from a deficiency of HPRT, the enzyme that recycles hypoxanthine and guanine. Without functional HPRT, free purines cannot be salvaged and instead flow down the degradation pathway, ultimately being converted to uric acid. At the same time, de novo purine synthesis ramps up because the normal inhibitory signals from salvaged nucleotides are absent. The result is massive uric acid overproduction. All HPRT-deficient patients develop hyperuricemia, kidney stones, and gout, and those with near-complete enzyme loss also exhibit severe neurological symptoms including involuntary movements and compulsive self-injurious behavior.13PubMed Central. Hypoxanthine-guanine phosophoribosyltransferase (HPRT) deficiency: Lesch-Nyhan syndrome
Even without a genetic salvage defect, the final step of purine degradation is a common source of trouble. In humans, the enzyme xanthine oxidoreductase converts hypoxanthine to xanthine and then to uric acid, which is the end product of purine metabolism because we lack the enzyme (uricase) that most other mammals use to break uric acid down further.14PubMed Central. Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview When uric acid production exceeds the kidneys’ ability to excrete it, serum levels rise and crystals can deposit in joints, triggering the inflammatory pain of gout. Xanthine oxidoreductase activity has also been linked to broader metabolic disturbances, including associations with obesity, insulin resistance, and liver dysfunction.15PubMed. New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity Drugs like allopurinol and febuxostat work by inhibiting xanthine oxidoreductase, reducing uric acid production at its source.16PubMed Central. The Role of Oxidative Stress in Hyperuricemia and Xanthine Oxidoreductase (XOR) Inhibitors
Immune Collapse From Toxic Nucleotide Buildup
Where Lesch-Nyhan shows what happens when salvage fails to recycle purines, adenosine deaminase (ADA) deficiency shows what happens when purine degradation fails. ADA normally breaks down adenosine and deoxyadenosine, channeling them toward excretion. Without ADA, these substrates and their phosphorylated derivatives, especially deoxyadenosine triphosphate (dATP), accumulate to toxic levels.17PubMed Central. Adenosine deaminase deficiency: a review Lymphocytes are particularly sensitive to this buildup because they have high levels of the kinases that convert deoxyadenosine into dATP. The accumulation triggers cell death throughout the immune system, resulting in severe combined immunodeficiency (SCID), the “bubble boy” disease.
Animal models confirm the severity of this metabolic poisoning. Mice engineered to lack ADA show dramatically elevated adenosine and deoxyadenosine in the thymus and blood, accompanied by severe thymus shrinkage and a near-total loss of T cells, mirroring the immune devastation seen in untreated human patients.18Scientific Reports. Metabolite and thymocyte development defects in ADA-SCID mice receiving enzyme replacement therapy ADA deficiency is one of the few genetic diseases for which gene therapy has shown real clinical success, precisely because restoring the missing enzyme in bone marrow stem cells allows the immune system to rebuild itself.
Why Parasites Make Good Drug Targets
Not every organism has both pathways. Some parasites, including all Leishmania species, completely lack the ability to synthesize purines de novo. They are entirely dependent on scavenging purines from their host through salvage enzymes.19PubMed Central. Purine salvage in Leishmania: complex or simple by design? This absolute dependence creates an attractive drug target: if you can block the parasite’s salvage enzymes without disrupting the host’s (which also has de novo synthesis to fall back on), you starve the parasite of a resource it cannot make for itself. Researchers have been working on this approach for over three decades, though converting the biological logic into a safe, effective drug has proven difficult because parasite salvage enzymes share structural similarities with human ones.
The same principle applies more broadly. Trypanosomes, which cause sleeping sickness and Chagas disease, and Plasmodium species, responsible for malaria, all have constrained nucleotide synthesis capacities that differ from their hosts. Identifying and exploiting those differences remains an active area of antiparasitic drug design.
How Viruses Hijack Nucleotide Production
Viruses face a different version of the nucleotide supply problem. They carry minimal or no metabolic machinery of their own, so they depend on the host cell’s nucleotide pools to replicate their genomes. Many viruses go further than passive dependence: they actively reprogram host cell metabolism to boost nucleotide production beyond what the cell would normally sustain.20PubMed Central. Viral Reprogramming of Nucleotide Synthesis and Its Impact on Viral Infection This can involve upregulating de novo synthesis enzymes, redirecting carbon and nitrogen metabolism to feed nucleotide precursors, or suppressing the host cell’s normal feedback inhibition so that nucleotide production runs unchecked.
This viral manipulation of nucleotide pathways is one reason why several antiviral drugs are nucleoside analogs, molecules that mimic natural nucleosides closely enough to get incorporated into viral DNA or RNA but then cause chain termination or lethal mutations. Acyclovir for herpes, sofosbuvir for hepatitis C, and remdesivir for SARS-CoV-2 all work on this principle. Understanding how viruses alter host nucleotide metabolism also opens the door to a different class of antivirals: drugs that block the metabolic reprogramming itself rather than mimicking a nucleoside.
Tumors and the Surprising Role of Dietary Purines
Cancer cells need enormous quantities of nucleotides to sustain their rapid division, and the conventional wisdom held that they meet this demand primarily through de novo synthesis. Quantitative metabolic tracing in living animals has challenged that assumption. De novo synthesis and salvage contribute comparably to the nucleotide pools of tumors, and circulating purines from the diet or from tissue turnover elsewhere in the body are major suppliers.21Cell. Purine salvage pathway complements de novo synthesis in maintaining nucleotide pools and promoting tumor growth Adenine and inosine carried in the bloodstream proved to be the most effective precursors, while hypoxanthine, despite being abundant in blood, was rapidly degraded and poorly used.5PubMed Central. De novo and salvage purine synthesis pathways across tissues and tumors
This finding matters for cancer treatment strategy. If tumors relied solely on de novo synthesis, blocking that pathway with drugs like methotrexate or mycophenolic acid should be sufficient. But if salvage provides a substantial backup supply, tumors might partially resist de novo inhibitors by scavenging more purines from the bloodstream. It also raises questions about whether dietary purine intake influences tumor growth, a topic that is far from settled but now has a plausible metabolic rationale.
Nucleotides Before Life
The question of how nucleotides first appeared on Earth, before any enzymes existed to synthesize them, is one of the central puzzles in origin-of-life research. Modern cells use elaborate enzymatic machinery to build nucleotides, but the earliest nucleotides must have formed through purely chemical processes. Experimental work simulating early Earth conditions has demonstrated that plausible proto-nucleotides can form abiotically, though the routes are messy and produce a mix of related but different molecules.22PubMed Central. Searching for lost nucleotides of the pre-RNA World with a self-refining model of early Earth
One major challenge is that prebiotic chemistry does not produce pure ribonucleotides. It also generates arabinonucleotides and deoxyribonucleotides, molecules with slightly different sugars. If early oligonucleotides were stitched together from such a mixed pool, how did relatively pure RNA eventually emerge? Template-copying experiments offer one possible answer: when a heterogeneous mix of activated nucleotides is used for primer extension, arabinonucleotides are incorporated far more slowly than ribonucleotides, meaning that the copying process itself acts as a filter that enriches the products in RNA.23Journal of the American Chemical Society. A Model for the Emergence of RNA from a Prebiotically Plausible Mixture of Ribonucleotides, Arabinonucleotides, and 2′-Deoxynucleotides The modern enzymatic pathways for nucleotide synthesis, with their exquisite specificity and feedback regulation, would have evolved later, replacing and refining what chemistry alone could accomplish.